After joining the Tympanogen team as a member of the Virginia Bio STEM2VA 2022 cohort, Emily Wandling combines her background in biochemistry with biomaterials expertise to develop novel and regenerative therapeutics that translate into clinical applications, by fusing the realms of biology and engineering. She completed her Master’s Thesis in Dr. Rebecca Heise’s laboratory at Virginia Commonwealth University (VCU), where she synthesized antimicrobial nanoparticles from the extracellular matrix to stimulate the healing of injured lung tissue. She received her BS in Biochemistry and Molecular Biology from Sweet Briar College and her MS in Biomedical Engineering from VCU.